CEL-SCI logo

CVM - CEL-SCI News Story

$9.66 0.7  8.3%

Last Trade - 3:04pm

Sector
Healthcare
Size
Small Cap
Market Cap £289.4m
Enterprise Value £264.5m
Revenue £21.5k
Position in Universe 4050th / 7335

BUZZ-CEL-SCI Corp shares tumble after drug trial update

Mon 28th June, 2021 4:47pm
** Shares in CEL-SCI Corp  CVM.A , an immunotherapy company
working on a treatment for head and neck cancer patients, down
43.7% at $14.13, on track for its biggest one-day pct decline
ever after its drug study did not meet its goals
    ** CEL-SCI announced that complete study population to which
the Multikine treatment regimen was administered was compared to
 control, study did not achieve primary endpoint of 10%
improvement in overall survival  urn:newsml:reuters.com:*:nBw4PpRnva
    ** The company said however that since a lower risk subgroup
the treatment exceeded the goal it plans to seek FDA approval
for this population 
    ** After CVM rose to a high of $27.28 right after the market
open the stock soon sank to a low of $9 before regaining some
ground. Trading volume was 10.4 times 10-DMA 




 (Reporting By Sinéad Carew)
 ((sinead.carew@thomsonreuters.com; +1 (646) 223 6186; Reuters
Messaging: sinead.carew.thomsonreuters.com@reuters.net))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.